In terms of participant flow, 497 individuals called and completed the phone screen, 186 were eligible on the phone screen and attended the in-person baseline screening session, and 132 of these met all screening criteria and were randomized to either an immediate treatment (n = 80) or delayed treatment control condition (n = 52). Of those randomized, 111 participants provided usable physiological data (66 in the treatment group, 45 in the control group), with the remainder excluded due to equipment failure (11), to dropping out after the orientation session (7), or to experimental noncompliance (3). Participants provided informed consent and the protocol was approved by the University of Texas MD Anderson Cancer Center’s Institutional Review Board.
